NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future.

Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at hepatology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References:

References are available here

Disclosures:

Prof. Philip Newsome declares the following:

Consultant on behalf of the University of Birmingham: Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals

Grants/Research Support recipient: Novo Nordisk, Boehringer Ingelheim

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Id. d’épisode : 1000569642571

GUID : cae6f5b5-1b13-4347-8fd4-c4516dc2cce0

Date de publication : 7/6/2022 à 10:14:39